Author: "B. Doyle" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"B. Doyle"' showing total 750 results

Start Over Author "B. Doyle"

750 results on '"B. Doyle"'

1. Low-complexity methods to mitigate the impact of environmental variables on low-cost UAS-based atmospheric carbon dioxide measurements

Author: G. Britto Hupsel de Azevedo, B. Doyle, C. A. Fiebrich, and D. Schvartzman
Subjects: Environmental engineering, TA170-171, Earthwork. Foundations, TA715-787
Abstract: This article assesses the individual and joint impact of pressure, temperature, and relative humidity on the accuracy of atmospheric CO2 measurements collected by unmanned aerial systems (UASs) using low-cost commercial non-dispersive infrared (NDIR) sensors. We build upon previous experimental results in the literature and present a new dataset with increased gradients for each environmental variable to match the abrupt changes found in UAS-based atmospheric vertical profiles. As a key contribution, we present a low-complexity correction procedure to mitigate the impact of these variables and reduce errors in this type of atmospheric CO2 measurement. Our findings support the use of low-cost NDIR sensors for UAS-based atmospheric CO2 measurements as a complementary in situ tool for many scientific applications.
Published: 2022
Full Text: View/download PDF

2. Autosomal dominant tubulointerstitial kidney disease (ADTKD) in Ireland

Author: S. Cormican, D. M. Connaughton, C. Kennedy, S. Murray, M. Živná, S. Kmoch, N. K. Fennelly, P. O’Kelly, K. A. Benson, E. T. Conlon, G. Cavalleri, C. Foley, B. Doyle, A. Dorman, M. A. Little, P. Lavin, K. Kidd, A. J. Bleyer, and P. J. Conlon
Subjects: adtkd, genetic, muc-1, umod, chronic kidney disease, hnf-1b, urinary smear, frameshift, Diseases of the genitourinary system. Urology, RC870-923
Abstract: Introduction: Autosomal dominant tubulointerstitial kidney disease (ADTKD) is a rare genetic cause of renal impairment resulting from mutations in the MUC1, UMOD, HNF1B, REN, and SEC61A1 genes. Neither the national or global prevalence of these diseases has been determined. We aimed to establish a database of patients with ADTKD in Ireland and report the clinical and genetic characteristics of these families. Methods: We identified patients via the Irish Kidney Gene Project and referral to the national renal genetics clinic in Beaumont Hospital who met the clinical criteria for ADTKD (chronic kidney disease, bland urinary sediment, and autosomal dominant inheritance). Eligible patients were then invited to undergo genetic testing by a variety of methods including panel-based testing, whole exome sequencing and, in five families who met the criteria for diagnosis of ADTKD but were negative for causal genetic mutations, we analyzed urinary cell smears for the presence of MUC1fs protein. Results: We studied 54 individuals from 16 families. We identified mutations in the MUC1 gene in three families, UMOD in five families, HNF1beta in two families, and the presence of abnormal MUC1 protein in urine smears in three families (one of which was previously known to carry the genetic mutation). We were unable to identify a mutation in 4 families (3 of whom also tested negative for urinary MUC1fs). Conclusions: There are 4443 people with ESRD in Ireland, 24 of whom are members of the cohort described herein. We observe that ADTKD represents at least 0.54% of Irish ESRD patients.
Published: 2019
Full Text: View/download PDF

3. The CASEL Framework and Christian Schools: Using a Hermeneutical Tool to Determine Worldview Alignment

Author: Jill L. Swisher and Lori B. Doyle
Abstract: This article aims to utilize an adapted version of Trentham's Inverse Consistency Protocol (ICP) as a way in which any ecclesial organization can act productively when confronted with seemingly controversial paradigms such as social emotional learning (SEL). The ICP can help Christian leaders discern potential areas of inconsistency or affirm authentic congruence with an organization's faith tradition. Tenets from the Collaborative for Academic, Social, and Emotional Learning (CASEL) were submitted through the four-step protocol. Findings suggest that CASEL is a valuable framework when applied authentically and that ICP is a constructive tool for engaging in the social sciences with integrity.
Published: 2024
Full Text: View/download PDF

4. Coaching and Coursework Focused on Teacher-Child Interactions during Language/Literacy Instruction: Effects on Teacher Outcomes and Children's Classroom Engagement

Author: Jason T. Downer, Nicole B. Doyle, Robert C. Pianta, Margaret Burchinal, Samuel Field, Bridget K. Hamre, Jennifer LoCasale-Crouch, Carollee Howes, Karen LaParo, and Catherine Scott-Little
Abstract: A sample of 496 early childhood teachers was assigned randomly in two phases to a series of professional development (PD) interventions. Phase I intervention was a 14-week course on effective teacher-child interactions. Participants were then re-randomized into Phase II intervention, which consisted of individual, interactions-focused coaching. Impacts of the course, coaching, and their combination were evaluated relative to business-as-usual controls on knowledge of effective interactions, skill in detecting effective interactions, observed teacher-child interactions, beliefs about intentional teaching, and children's classroom engagement. "Research Findings:" Teachers exposed to the course demonstrated greater knowledge of and skills in detecting effective teacher child-interactions, and displayed higher quality instructional support in their interactions with children during the year following the course. Teachers who received coaching were also observed to display higher levels of instructional support and children in their classrooms displayed more positive engagement with adults. However, neither teachers nor children appeared to gain additional benefit from the combination of the course and coaching. "Practice or Policy:" The results have important implications for efforts to systematically and efficiently improve the quality of early childhood programs through the delivery of PD that is directly aligned with teachers' classroom interactions.
Published: 2024
Full Text: View/download PDF

5. Understanding Teachers' Emotion Regulation Strategies and Related Teacher and Classroom Factors

Author: Nicole B. Doyle, Jason T. Downer, and Sara E. Rimm-Kaufman
Abstract: Today's teachers face intense stress (Robinson et al. in School Mental Health 15(1):78-89, 2023), which means they often need to regulate strong emotions, like frustration and anxiety, in the classroom. Given the importance of this skill for classroom life, it is essential that we gain a more nuanced understanding of teachers' emotion regulation (ER). The teacher ER literature is growing, and we aim to contribute meaningfully in three ways. First, we examine two general ER strategies (cognitive reappraisal and expressive suppression) descriptively in a sample of 190 public school teachers (grades K-6) from 33 elementary schools. Second, we explore whether these two ER strategies are correlated with important teacher (burnout, years of experience) and classroom (class size) factors. Third, we examine whether these ER strategies are linked to observed emotionally supportive classroom interactions. Teachers in this sample reported frequent use of cognitive reappraisal and relatively infrequent use of expressive suppression in general. These two ER strategies were not significantly correlated with one another. Teachers reporting greater use of cognitive reappraisal reported less burnout, while teachers reporting greater use of expressive suppression reported more burnout. Teachers with more years of experience also reported greater use of cognitive reappraisal. Contrary to our hypotheses, cognitive reappraisal and expressive suppression were not related to class size and did not predict unique variance in observed emotionally supportive interactions. Implications for teacher supports and interventions are discussed.
Published: 2024
Full Text: View/download PDF

6. Nearshore wave buoy data from southeastern Australia for coastal research and management

Author: Michael A. Kinsela, Bradley D. Morris, Timothy C. Ingleton, Thomas B. Doyle, Michael D. Sutherland, Neil E. Doszpot, Jeff J. Miller, Stephen F. Holtznagel, Mitchell D. Harley, and David J. Hanslow
Subjects: Science
Abstract: Abstract Wind wave observations in shallow coastal waters are essential for calibrating, validating, and improving numerical wave models to predict sediment transport, shoreline change, and coastal hazards such as beach erosion and oceanic inundation. Although ocean buoys and satellites provide near-global coverage of deep-water wave conditions, shallow-water wave observations remain sparse and often inaccessible. Nearshore wave conditions may vary considerably alongshore due to coastline orientation and shape, bathymetry and islands. We present a growing dataset of in-situ wave buoy observations from shallow waters (
Published: 2024
Full Text: View/download PDF

7. Using Teacher Presence in Online Higher Education to Foster Global Citizenship among Adult Learners

Author: Tanya M. Tarbutton and Lori B. Doyle
Subjects: global citizenship, online education, adult learners, higher education, community of inquiry, teacher presence, Education
Abstract: Higher education institutions must recognize the responsibility to support online adult learners as members of a larger global community and technological advancements have made this a reality. COVID-19 restrictions to in-person learning highlighted the need for online learning platforms that promote the benefits of teacher presence, consider the tenets of the Community of Inquiry model, and commit to the principles of andragogy. A need to explore the possibilities for fostering global citizenship among adult learners in online higher education environments has been identified as a problem space and a methodological approach will be used to connect findings from the literature with best practices for practitioners. Global citizenship is not a new concept; however, current and worldwide events have created a renewed dedication to the construct. Discussions based on the literature and established theoretical frameworks will precede practical implications for directors, course designers, and instructors. Online education will be described as ripe with opportunities for higher education institutions to foster global citizenship among adult learners.
Published: 2023
Full Text: View/download PDF

8. Foredune erosion, overtopping and destruction in 2022 at Bengello Beach, southeastern Australia

Author: Thomas S. N. Oliver, Michael A. Kinsela, Thomas B. Doyle, and Roger F. McLean
Subjects: coastal storm, backshore erosion, storm impacts, beach erosion, foredune erosion, Harbors and coast protective works. Coastal engineering. Lighthouses, TC203-380, Oceanography, GC1-1581
Abstract: The beach–foredune system at Bengello Beach has been monitored monthly to bimonthly at four profiles (P1–P4) since 1972 and documented the building of a foredune. This paper addresses the remarkable changes which occurred in 2022 as storm waves overtopped and trimmed this foredune at all profiles, then later removed this entire feature at two of the profiles (P3, P4) but not the others (P1, P2). Wave parameters for these storm events, measured by deepwater and nearshore wave buoys, enable a comparison of storm characteristics and resulting beach–foredune impact. During the storm event which destroyed the foredune, nearshore wave height exceeded deepwater wave height, in contrast with other storms that year. The beach–foredune lost 78 m3/m in 2022 and the notable 1974 storms that impacted this coastline resulted in 95 m3/m volume loss. During 2023, beach recovery has occurred, but not rebuilt the foredune. It had persisted for ~40 years enduring many other severe storm events, and the coastal protection afforded by the dune system has been compromised. This highlights the need to consider dune morphology in assessments of erosion hazard and inundation risk along similar coastlines.
Published: 2024
Full Text: View/download PDF

9. Vaborbactam increases meropenem susceptibility in Pseudomonas aeruginosa clinical isolates displaying MexXY and AmpC upregulation

Author: Mariana Castanheira, Timothy B. Doyle, Cory M. Hubler, Sean DeVries, and Dee Shortridge
Subjects: P. aeruginosa, β-lactam/β-lactamase inhibitor combinations, efflux, Microbiology, QR1-502
Abstract: ABSTRACT To evaluate the resistance mechanisms among Pseudomonas aeruginosa clinical isolates exhibiting meropenem (MEM) MIC values higher than meropenem-vaborbactam (MEV). P. aeruginosa clinical isolates collected in US hospitals from 2014 to 2019 were susceptibility tested. Whole-genome and transcriptome sequencing were performed. Results were analyzed for strain typing, acquired β-lactamases, and mutations in chromosomal genes; gene expression was measured for known β-lactam resistance contributors. Results were compared to a control group of 10 P. aeruginosa isolates displaying MIC values at 8 mg/L for meropenem ± vaborbactam (MEM = MEV). Out of 88 isolates displaying MEM > MEV, 33 (37.5%) isolates had reproducibly lower MIC values for meropenem-vaborbactam compared to meropenem when retested. The expression of mexX, mexY, mexZ, and ampC was significantly greater among a higher percentage of the MEM > MEV isolates. Furthermore, the association of mexXY and ampC overexpression was detected in 17/33 MEM > MEV isolates and only 1/10 MEM = MEV isolate. In addition, the Pseudomonas-derived cephalosporinase amino acid substitution R79Q was detected among 33.3% of the isolates displaying MEM > MEV, and none of the isolates displayed MEM = MEV. Other resistance mechanisms were not observed or were equally observed in both groups. In rare cases, vaborbactam plays a role in lowering the meropenem MIC values in P. aeruginosa clinical isolates likely due to the inhibition of the AmpC gene that was overexpressed in the presence of upregulation of MexXY with or without alterations in the AmpC gene. IMPORTANCE Pseudomonas aeruginosa isolates are intrinsically resistant to multiple antimicrobial agents and meropenem is an important therapeutic option to treat infections caused by this organism. Meropenem-vaborbactam activity is similar to that of meropenem alone against P. aeruginosa isolates. Isolates belonging to this species that display lower meropenem-vaborbactam compared to meropenem are rare. We initiated this study to understand the resistance mechanisms that could lead to lower meropenem-vaborbactam MIC values when compared to meropenem alone. We documented that isolates displaying lower meropenem-vaborbactam exhibited overexpression of MexXY and AmpC. In addition, isolates displaying the R79Q PDC (AmpC) mutation were more likely to display lower meropenem-vaborbactam when compared to isolates displaying the same MIC values for these agents.
Published: 2023
Full Text: View/download PDF

10. The plethora of resistance mechanisms in Pseudomonas aeruginosa: transcriptome analysis reveals a potential role of lipopolysaccharide pathway proteins to novel β-lactam/β-lactamase inhibitor combinations

Author: Mariana Castanheira, Timothy B. Doyle, Cory M. Hubler, Timothy D. Collingsworth, Sean DeVries, and Rodrigo E. Mendes
Subjects: Pseudomonas aeruginosa, Transcriptome, β-lactam resistance, Microbiology, QR1-502
Abstract: ABSTRACT: Objectives: Whole genome and transcriptome analysis of 213 Pseudomonas aeruginosa isolates resistant to antipseudomonal β-lactams collected in 30 countries was performed to evaluate resistance mechanisms against these agents. Methods: Isolates were susceptibility tested by reference broth microdilution. Whole genome and transcriptome sequencing were performed, and data were analysed using open-source tools. A statistical analysis of changes in the expression of >5500 genes was compared to the expression of PAO1. Results: The high-risk clones ST235 and ST111 were the most prevalent among >90 sequence types (STs). Metallo-β-lactamase (MBLs) genes were detected in 40 isolates. AmpC and MexXY were the most common genes overexpressed in approximately 50% of the 173 isolates that did not carry MBLs. Isolates overexpressing pmrA and pmrB, the norspermidine production genes speD2 and speE2, and the operon arnBCADTEF-ugd were noted among strains resistant to ceftolozane-tazobactam and ceftazidime-avibactam, despite the lack of polymyxin resistance often associated to increased expression of these genes. Overexpression of MuxABC-OpmB, OprG, and OprE proteins were associated with resistance to ceftolozane-tazobactam in addition to the usual genes involved in cephalosporin, monobactam, and carbapenem resistance. Statistical analysis identified discrete mutations in ArmZ, OprD, and AmpC that correlated to antipseudomonal β-lactam resistance. Conclusions: P. aeruginosa resistance mechanisms are complex. This analysis suggests the role of multiple genes in resistance to antipseudomonal β-lactams, including some not commonly described.
Published: 2022
Full Text: View/download PDF

11. Closing the Gap in Prophylactic Treatment of Duodenal Endoscopic Submucosal Dissection Defects

Author: John B. Doyle and Kavel Visrodia
Subjects: Diseases of the digestive system. Gastroenterology, RC799-869
Published: 2023
Full Text: View/download PDF

12. Endoscopic Ultrasound-Guided Biliary Drainage

Author: John B. Doyle and Amrita Sethi
Subjects: endoscopic ultrasound, biliary obstruction, choledochoduodenostomy, hepaticogastrostomy, Medicine
Abstract: Endoscopic retrograde cholangiopancreatography (ERCP) and percutaneous transhepatic biliary drainage (PTBD) are currently first- and second-line therapeutic options, respectively, for the relief of biliary obstruction. In recent years, however, endoscopic ultrasound-guided biliary drainage (EUS-BD) has become an established alternative therapy for biliary obstruction. There are multiple different techniques for EUS-BD, which can be distinguished based on the access point within the biliary tree (intrahepatic versus extrahepatic) and the location of stent placement (transenteric versus transpapillary). The clinical and technical success rates of biliary drainage for EUS-BD are similar to both ERCP and PTBD, and complication rates are favorable for EUS-BD relative to PTBD. As EUS-BD becomes more widely practiced and endoscopic tools continue to advance, the outcomes will likely improve, and the breadth of indications for EUS-BD will continue to expand.
Published: 2023
Full Text: View/download PDF

13. Industrial Bank

Author: Mitchell, B. Doyle. Author, Mitchell, Patricia A., 1960- Author, Page, Lisa Frazier. Author, and Mitchell, B. Doyle. Author
Published: 2012

14. Identification and Characterization of ML321: A Novel and Highly Selective D2 Dopamine Receptor Antagonist with Efficacy in Animal Models That Predict Atypical Antipsychotic Activity

Author: R. Benjamin Free, Ashley N. Nilson, Noelia M. Boldizsar, Trevor B. Doyle, Ramona M. Rodriguiz, Vladimir M. Pogorelov, Mayako Machino, Kuo Hao Lee, Jeremiah W. Bertz, Jinbin Xu, Herman D. Lim, Andrés E. Dulcey, Robert H. Mach, James H. Woods, J Robert Lane, Lei Shi, Juan J. Marugan, William C. Wetsel, and David R. Sibley
Subjects: Pharmacology, Pharmacology (medical)
Published: 2022

15. Liver transplantation as a new standard of care in patients with perihilar cholangiocarcinoma?

Author: Eva Breuer, Matteo Mueller, Majella B. Doyle, Liu Yang, Sarwa Darwish Murad, Imran J. Anwar, Shaheed Merani, Ashley Limkemann, Heithem Jeddou, Steven C. Kim, Victor López-López, Ahmed Nassar, Frederik J.H. Hoogwater, Eric Vibert, Michelle L. De Oliveira, Daniel Cherqui, Robert J. Porte, Joseph F. Magliocca, Lutz Fischer, Constantino Fondevila, Krzysztof Zieniewicz, Pablo Ramírez, David P. Foley, Karim Boudjema, Austin D. Schenk, Alan N. Langnas, Stuart Knechtle, Wojciech G. Polak, C. Burcin Taner, William C. Chapman, Charles B. Rosen, Gregory J. Gores, Philipp Dutkowski, Julie K. Heimbach, Pierre-Alain Clavien, Gastroenterology & Hepatology, Surgery, and Groningen Institute for Organ Transplantation (GIOT)
Subjects: Complications, Liver transplantation, CCI, Benchmarks, Standard of Care, Outcomes, Mayo-protocol, Cholangiocarcinoma, Benchmarking, Bile Duct Neoplasms, Humans, Surgery, Perihilar cholangiocarcinoma, Klatskin Tumor
Abstract: Objective: To define benchmark values for liver transplantation (LT) in patients with perihilar cholangiocarcinoma (PHC) enabling unbiased comparisons.Background: Transplantation for PHC is used with reluctance in many centers and even contraindicated in several countries. Although benchmark values for LT are available, there is a lack of specific data on LT performed for PHC.Methods: PHC patients considered for LT after Mayo-like protocol were analyzed in 17 reference centers in 2 continents over the recent 5-year period (2014–2018). The minimum follow-up was 1 year. Benchmark patients were defined as operated at high-volume centers (≥ 50 overall LT/year) after neoadjuvant chemoradiotherapy, with a tumor diameter Results: One hundred thirty-four consecutive patients underwent LT after completion of the neoadjuvant treatment. Of those, 89.6% qualified as benchmark cases. Benchmark cutoffs were 90-day mortality ≤ 5.2%; comprehensive complication index at 1 year of ≤ 33.7; grade ≥ 3 complication rates ≤ 66.7%. These values were better than benchmark values for other indications of LT. Five-year disease-free survival was largely superior compared with a matched group of nodal negative patients undergoing curative liver resection (n = 106) (62% vs 32%, P < 0.001).Conclusion: This multicenter benchmark study demonstrates that LT offers excellent outcomes with superior oncological results in early stage PHC patients, even in candidates for surgery. This provocative observation should lead to a change in available therapeutic algorithms for PHC.
Published: 2022

16. Body mass index and additional risk factors for cancer in adults with cystic fibrosis

Author: Rita M. Knotts, Zhezhen Jin, John B. Doyle, Claire Keating, Emily DiMango, and Julian A. Abrams
Subjects: Cancer Research, Oncology
Published: 2022

17. Liver Transplantation After Hepatic Artery Infusion Pump Therapy: Single-Center Experience and Technical Considerations

Author: Angela L. Hill, Darren R. Cullinan, Ola Ahmed, Neeta Vachharajani, Meranda D. Scherer, Franklin Olumba, Adeel S. Khan, William C. Chapman, and Majella B. Doyle
Subjects: Oncology, Surgery
Published: 2023

18. Engineered phage with antibacterial CRISPR–Cas selectively reduce E. coli burden in mice

Author: Yilmaz Emre Gencay, Džiuginta Jasinskytė, Camille Robert, Szabolcs Semsey, Virginia Martínez, Anders Østergaard Petersen, Katja Brunner, Ana de Santiago Torio, Alex Salazar, Iszabela Cristiana Turcu, Melissa Kviesgaard Eriksen, Lev Koval, Adam Takos, Ricardo Pascal, Thea Staffeldt Schou, Lone Bayer, Tina Bryde, Katja Chandelle Johansen, Emilie Glad Bak, Frenk Smrekar, Timothy B. Doyle, Michael J. Satlin, Aurelie Gram, Joana Carvalho, Lene Jessen, Björn Hallström, Jonas Hink, Birgitte Damholt, Alice Troy, Mette Grove, Jasper Clube, Christian Grøndahl, Jakob Krause Haaber, Eric van der Helm, Milan Zdravkovic, and Morten Otto Alexander Sommer
Subjects: Biomedical Engineering, Molecular Medicine, Bioengineering, Applied Microbiology and Biotechnology, Biotechnology
Abstract: Antibiotic treatments have detrimental effects on the microbiome and lead to antibiotic resistance. To develop a phage therapy against a diverse range of clinically relevant Escherichia coli, we screened a library of 162 wild-type (WT) phages, identifying eight phages with broad coverage of E. coli, complementary binding to bacterial surface receptors, and the capability to stably carry inserted cargo. Selected phages were engineered with tail fibers and CRISPR–Cas machinery to specifically target E. coli. We show that engineered phages target bacteria in biofilms, reduce the emergence of phage-tolerant E. coli and out-compete their ancestral WT phages in coculture experiments. A combination of the four most complementary bacteriophages, called SNIPR001, is well tolerated in both mouse models and minipigs and reduces E. coli load in the mouse gut better than its constituent components separately. SNIPR001 is in clinical development to selectively kill E. coli, which may cause fatal infections in hematological cancer patients.
Published: 2023

19. COVID Vaccination Status and Operative Outcomes after Kidney Transplantation

Author: Bradley S Kushner, Maria B Doyle, Adeel S Khan, Yiing Lin, Tarek Alhamad, Jennifer Yu, William C Chapman, and Jason R Wellen
Subjects: Surgery
Published: 2023

20. Understanding High Quality Teacher-Student Interactions in High Needs Elementary Schools: An Exploration of Teacher, Student, and Relational Contributors

Author: Nicole B. Doyle, Jason T. Downer, Joshua L. Brown, and Amy E. Lowenstein
Subjects: Developmental and Educational Psychology, Education
Published: 2022

21. Using Teacher Presence in Online Higher Education to Foster Global Citizenship among Adult Learners

Author: Tanya M. Tarbutton and Lori B. Doyle
Subjects: Education
Abstract: Higher education institutions must recognize the responsibility to support online adult learners as members of a larger global community and technological advancements have made this a reality. COVID-19 restrictions to in-person learning highlighted the need for online learning platforms that promote the benefits of teacher presence, consider the tenets of the Community of Inquiry model, and commit to the principles of andragogy. A need to explore the possibilities for fostering global citizenship among adult learners in online higher education environments has been identified as a problem space and a methodological approach will be used to connect findings from the literature with best practices for practitioners. Global citizenship is not a new concept; however, current and worldwide events have created a renewed dedication to the construct. Discussions based on the literature and established theoretical frameworks will precede practical implications for directors, course designers, and instructors. Online education will be described as ripe with opportunities for higher education institutions to foster global citizenship among adult learners. Keywords: global citizenship, online education, adult learners, higher education, Community of Inquiry, teacher presence
Published: 2022

22. Virtual Ancillary Faculty

Author: Lori B. Doyle and Tanya M. Tarbutton
Abstract: Virtual ancillary faculty are instrumental in delivering online instruction and fostering student success across higher education institutions. Program directors should create models of support using performance outcomes and verbal persuasion to foster self-efficacy in order to help instructors avoid feelings of depersonalization that can lead to burnout. The job-demands resources model has been shown to support supervisor efforts to recognize work-related demands in order to provide purposeful resources. The authors of this chapter work as program directors and share examples, rationale, and expertise through a case study approach which highlights best practices for working with virtual ancillary faculty including an in-depth examination of teacher evaluation and professional development strategies.
Published: 2023

23. Modified Foredune Eco-Morphology in Southeast Australia

Author: Thomas B. Doyle and Colin D. Woodroffe
Subjects: Management, Monitoring, Policy and Law, Aquatic Science, Oceanography
Published: 2023

24. The learning curve of deceased donor liver transplant during fellowship training

Author: William C. Chapman, Sarah Matson, Meranda Scherer, Sandra Garcia-Aroz, Majella B. Doyle, Jason M Wellen, Ola Ahmed, Neeta Vachharajani, Heidy Cos, Adeel S. Khan, and Surendra Shenoy
Subjects: Adult, Transplantation, Retrospective review, medicine.medical_specialty, Deceased donor, business.industry, medicine.medical_treatment, Objective data, Liver transplantation, Warm ischemia, Liver Transplantation, Surgery, Transplant surgery, Living Donors, medicine, Humans, Immunology and Allergy, Pharmacology (medical), Fellowships and Scholarships, business, Fellowship training, Learning Curve, Retrospective Studies
Abstract: Liver transplantation (LT) is a complex operation that most transplant surgeons learn in fellowship. Training varies as there is lack of objective data that can be used to standardize teaching. We performed a retrospective review of our adult LT database with aim of looking at fellow's experience. Using American Society of Transplant Surgery cutoff of, at least 45 LT during fellowship, data for first 45 LT were compared to LT 45-90. Fellow's cases were also clustered in sequential groups of 15 LT and analyzed to estimate the learning curve (LC). Comparison of LT 1-45 with LT 46-90 showed significantly lower total operative times (TOT) (324 vs. 344 min) and warm ischemia times (WIT) (28 vs. 31 min) in the 45-90 group. Rates of biliary complications (23.8% vs. 16.4%) and bile leaks alone (10.3% vs. 5.5%) were significantly higher for first 45 LT. Analysis of fellows experience in sequential clusters of 15 LT showed decreasing TOT, WIT, biliary complications and rates of unplanned return to the OR with progression of fellowship. This study validates the current ASTS requirement of at least 45 LT. LC generated using these data can help individualize training and optimize outcomes through identification of areas in need of improvement.
Published: 2021

25. Correction to: Absence of ferromagnetic behaviour in Mn implanted ZnO

Author: K. Bharuth-Ram, T. B. Doyle, V. Adoons, and C. Ronning
Subjects: Nuclear and High Energy Physics, Physical and Theoretical Chemistry, Condensed Matter Physics, Atomic and Molecular Physics, and Optics
Published: 2022

26. Absence of ferromagnetic behaviour in Mn implanted ZnO

Author: K. Bharuth-Ram, T. B. Doyle, V. Adoons, and C. Ronning
Subjects: Nuclear and High Energy Physics, Physical and Theoretical Chemistry, Condensed Matter Physics, Atomic and Molecular Physics, and Optics
Published: 2022

27. Identification and Characterization of ML321: a Novel and Highly Selective D2Dopamine Receptor Antagonist with Efficacy in Animal Models that Predict Atypical Antipsychotic Activity

Author: R. Benjamin Free, Ashley N. Nilson, Noelia M. Boldizsar, Trevor B. Doyle, Ramona M. Rodriguiz, Vladimir M. Pogorelov, Mayako Machino, Kuo Hao Lee, Jeremiah W. Bertz, Jinbin Xu, Herman D. Lim, Andrés E. Dulcey, Robert H. Mach, James H. Woods, J Robert Lane, Lei Shi, Juan J. Marugan, William C. Wetsel, and David R. Sibley
Abstract: We have developed and characterized a novel D2R antagonist with exceptional GPCR selectivity – ML321. In functional profiling screens of 168 different GPCRs, ML321 showed little activity beyond potent inhibition of the D2R, and to a lesser extent the D3R, demonstrating excellent receptor selectivity. The D2R selectivity of ML321 may be related to the fact that, unlike other monoaminergic ligands, ML321 lacks a positively charged amine group and adopts a unique binding pose within the orthosteric binding site of the D2R. PET imaging studies in non-human primates demonstrated that ML321 penetrates the CNS and occupies the D2R in a dose-dependent manner. Behavioral paradigms in rats demonstrate that ML321 can selectively antagonize a D2R-mediated response (hypothermia) while not affecting a D3R-mediated response (yawning) using the same dose of drug, thus indicating exceptionalin vivoselectivity. We also investigated the effects of ML321 in animal models that are predictive of antipsychotic efficacy in humans. We found that ML321 attenuates both amphetamine- and phencyclidine-induced locomotor activity and restored pre-pulse inhibition (PPI) of acoustic startle in a dose-dependent manner. Surprisingly, using doses that were maximally effective in both the locomotor and PPI studies, ML321 was relatively ineffective in promoting catalepsy. Kinetic studies revealed that ML321 exhibits slow-on and fast-off receptor binding rates, similar to those observed with atypical antipsychotics with reduced extrapyramidal side effects. Taken together, these observations suggest that ML321, or a derivative thereof, may exhibit “atypical” antipsychotic activity in humans with significantly fewer side effects than observed with currently FDA-approved D2R antagonists.
Published: 2022

28. Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019

Author: Rodrigo E. Mendes, Jennifer M. Streit, Timothy B Doyle, Helio S. Sader, Francis F. Arhin, and Mariana Castanheira
Subjects: Microbiology (medical), Penicillin binding proteins, Sequence analysis, Klebsiella pneumoniae, Avibactam, Microbial Sensitivity Tests, Aztreonam, medicine.disease_cause, Ceftazidime, beta-Lactamases, Microbiology, chemistry.chemical_compound, Escherichia coli, medicine, AcademicSubjects/MED00740, Pharmacology (medical), Original Research, Pharmacology, biology, biology.organism_classification, Anti-Bacterial Agents, Drug Combinations, AcademicSubjects/MED00290, Latin America, Infectious Diseases, chemistry, AcademicSubjects/MED00230, Azabicyclo Compounds, Enterobacter cloacae, Bacteria
Abstract: Background The combination aztreonam/avibactam is currently under Phase 3 trials for the treatment of serious infections caused by Gram-negative bacteria including those with MBLs. Objectives To investigate the resistance mechanisms in Enterobacterales exhibiting aztreonam/avibactam MICs of ≥4 mg/L. Methods Among 8787 Enterobacterales, 17 (0.2%) isolates exhibited an aztreonam/avibactam MIC of ≥4 mg/L. Isolates were sequenced and screened for β-lactamases. Sequences of porins, penicillin-binding protein 3 (PBP3) and expression levels of AmpC and AcrA were evaluated. Results Eleven (11/4154 isolates; 0.26%) Escherichia coli, three (3/1981; 0.15%) Klebsiella pneumoniae and three (3/628; 0.5%) Enterobacter cloacae were identified. All E. coli showed either an ‘YRIK’ or ‘YRIN’ insertion in PBP3. In general, these isolates carried blaCMY and/or blaCTX-M variants, except for one isolate from Korea that also produced NDM-5 and one isolate from Turkey that produced OXA-48. Two DHA-1-producing K. pneumoniae overexpressed acrA and had a premature stop codon in either OmpK35 or OmpK36, whereas a third K. pneumoniae carried blaPER-2 and had a premature stop codon in OmpK35. All three E. cloacae expressed AmpC at levels ≥570-fold, but sequence analysis did not reveal known amino acid alterations associated with decreased avibactam binding or increased hydrolysis of β-lactams. Minor amino acid polymorphisms within OmpC, OmpF and PBP3 were noted among the E. cloacae. Conclusions A small number of isolates (0.2%) met the inclusion criteria. E. coli showed altered PBP3 as the most relevant resistance mechanism, whereas K. pneumoniae had multiple resistance mechanisms. Further investigations are needed to clarify resistance in E. cloacae.
Published: 2021

29. 2 Pre-hospital direct ambulance transfer has led to major improvements in timeliness of ppci in suspected stemi: temporal trends over an eight-year period in a designated PPCI centre

Author: Z Butt, B McGrath, D Cadogan, I Casserly, H McCann, J O’Neill, E Keelan, P Keelan, J Galvin, B Doyle, and G Blake
Published: 2022

30. The InBetweeners

Author: Colleen B. Doyle, Sam Blanckensee, Niamh Nestor, and Conor Buggy
Published: 2022

31. Prevalence of carbapenemase genes among carbapenem-nonsusceptible Enterobacterales collected in US hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agents

Author: Mariana Castanheira, Lalitagauri M Deshpande, Rodrigo E Mendes, Timothy B Doyle, and Helio S Sader
Subjects: General Medicine
Abstract: Objectives To evaluate the prevalence of acquired β-lactamase genes and susceptibility profiles of carbapenem-nonsusceptible Enterobacterales (CNSE) clinical isolates collected in US hospitals during a 5-year period. Methods Isolates were susceptibility tested by reference broth microdilution methods. Results were interpreted using CLSI breakpoints. Isolates displaying nonsusceptible MICs for imipenem or meropenem were categorized as CNSE. CNSE isolates were screened for β-lactamase-encoding genes using whole-genome sequencing. New genes were cloned, expressed in an Escherichia coli background and susceptibility tested. Results A total of 450 (1.3%) isolates were CNSE. Klebsiella pneumoniae serine carbapenemase (KPC) production was the most common resistance mechanism among CNSE isolates: 281/450 (62.4%) carried blaKPC, including three new variants. OXA-48-like and metallo-β-lactamase (MBL) encoding genes were detected among seven and 12 isolates, respectively. Among MBL genes, blaNDM-1 was the most common, but blaNDM-5, blaVIM-1 and blaIMP-27 were also identified. 169 (37.6% of the CNSE) isolates did not produce carbapenemases. Ceftazidime/avibactam was the most active agent (95.0% to 100.0% susceptible) against CNSE isolates from all carbapenemase groups except MBL-producing isolates. Ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam inhibited 100.0%, 97.6% and 92.3% of the non-carbapenemase CNSE isolates, respectively. Among the three new blaKPC variants, one conferred resistance to ceftazidime/avibactam and low meropenem MIC results while the other two had profiles similar to blaKPC-2 or blaKPC-3. Conclusions A decline in carbapenemase production was noticed in US hospitals in the 5-year period analysed in this study. New β-lactam/β-lactamase inhibitor combinations tested had good activity against CNSE isolates.
Published: 2022

32. Prevalence of Adenomas on Surveillance Colonoscopies for Patients with a History of Colonic Polyps of Unknown Histology

Author: Benjamin Lebwohl, Anna Krigel, and John B Doyle
Subjects: medicine.medical_specialty, Adenoma, medicine.diagnostic_test, Physiology, business.industry, Gastroenterology, Colonoscopy, Histology, Colonic Polyp, Hepatology, medicine.disease, digestive system diseases, Colon polyps, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, otorhinolaryngologic diseases, medicine, 030211 gastroenterology & hepatology, Surveillance colonoscopy, business, Cohort study
Abstract: Guidelines for surveillance colonoscopy depend on polyp histology. When patients present to a new healthcare system and report a personal history of “colon polyps,” however, information on polyp histology is frequently unavailable. To assess adenoma prevalence in patients with a history of colonic polyps of unknown histology and to compare it to patients undergoing either screening colonoscopy or surveillance colonoscopy for known adenomatous polyps. This cohort study evaluated colonoscopies of patients ≥ 50 years of age over a 14-year period at a single institution. The exposure of interest was colonoscopy indication, categorized into three groups: screening colonoscopy, surveillance colonoscopy for history of colonic polyp(s) of unknown histology, and surveillance colonoscopy for history of adenoma(s). The primary outcome was adenoma detection rate. Multivariable logistic regression was used to assess the association between colonoscopy indication and adenoma detection rate. Of 31,856 colonoscopies, the adenoma prevalence was 26.1% for patients undergoing screening colonoscopy, 32.9% for patients with a history of polyps of unknown histology, and 41.9% for patients with a history of known adenomatous polyps. Relative to screening colonoscopies, there were higher odds of adenoma detection in surveillance colonoscopies for polyps of unknown histology (aOR compared to screening 1.42, 95% CI 1.30–1.55) and even higher odds among surveillance colonoscopies for a history of adenoma (aOR compared to screening 1.89, 95% CI 1.75–2.05). The adenoma prevalence on surveillance colonoscopy for patients with polyps of unknown histology was higher than that of screening colonoscopies but lower than that of surveillance colonoscopies for patients with adenomatous polyps.
Published: 2021

33. Percolation Behaviour in the Magnetic Permeability and Electrical Conductivity in Conducting Magnetic - Insulating Non Magnetic Binary Composites

Author: David S McLachlan, T B Doyle, and Godfrey Sauti
Subjects: Solid-State Physics
Abstract: Experimental results of the complex magnetic permeability (µ) and the electrical conductivity (σ) of a granular paramagnetic Gadolinium Gallium Garnet (GGG: 0.3–26 vol%) and Teflon (PTFE) system are presented and discussed in relation to previously published (conductivity) and unpublished (permeability) studies on granular Fe3O4 – talc and Ni – talc wax systems. In these systems plots of the real conductivity (σ'(sub m)) against the volume fraction (φ) lie on characteristic sigmoid curves that when fitted to the Two Exponent Phenomenological Percolation Equation (TEPPE) confirm the existence of “percolation microstructures” with critical volume fractions (φ(sub c)). The plots of the real and imaginary permeability (µ'(sub m)) and (µ"(sub m)) satisfactorily fit to the TEPPE using the φ(sub c) obtained in each case from the “conductivity” measurements. In all three cases the conductivity results gave the exponent t > 2, and the permeability results gave t < 1.
Published: 2018
Full Text: View/download PDF

34. 1078. Optimization of a 96-well Plate Format Assay to Evaluate Concentration-Dependent Activity of a Monoclonal Antibody Against the O Antigen O25b from ST131-H30 Escherichia coli

Author: Jill Lindley, Timothy B Doyle, Brian D VanScoy, Christopher M Rubino, Sujata M Bhavnani, Paul G Ambrose, and Mariana Castanheira
Subjects: Infectious Diseases, Oncology
Abstract: Background Escherichia coli ST131 is a major challenge for global human health. Among ST131 isolates, the H30 type is prevalent and displays multiple drug resistance to classes. A monoclonal antibody (mAb) specific for the O antigen, O25b, which is conserved in ST131-H30 clonal lineage, was developed for diagnostic and prophylactic therapy. We optimized a 96-well plate assay to test different concentrations of the mAb against E. coli clinical isolates. Methods Initial growth curves were performed against 69 ST131-O25b, 9 ST131-O25a, 32 ST131 non-O25, and 29 non-ST131 E. coli isolates in 40% active human serum (HS). Additional conditions evaluated for growth inhibition by the mAb included 3 media types, 3 HS sources, pH variations, addition of polysorbate 80 (P80), inoculum concentration, length of incubation, and varying calcium and magnesium concentrations. Once optimal parameters were established, the assay was miniaturized into a 96-well format and 12 ST131-O25b and 5 non-ST131 were tested. Fluorescence and visual reading using alamarBlue (AB), a cell metabolism indicator, were performed at 8 and 10h in addition to plating for viable colonies. Results After 10h incubation, only 36/69 (52.2%) ST131-O25b isolates exhibited visible growth in BHI plus 40% HS. A 2-part growth inhibition assay using BHI plus 50% HS and BHI with 25% HS without the addition of P80, calcium, or magnesium was considered the optimal growth condition for EC strains to test the effect of the mAb. By 10 hours, all ST131-O25b strains displayed a visual inhibition of growth between 0.3-5 mg/L of α-ST131 mAb and zero non-ST131 strains were inhibited (Figure). While reading AB on a fluorometer was more sensitive and less subjective than visual interpretation, both reading methods allow for endpoint determinations. Additionally, panels were able to go through one freeze-thaw cycle and still retain α-ST131:O25b mAb activity. Conclusion Concentration-dependent activity of a α-ST131:O25b mAb can be measured in vitro in a microtiter format; however, the growth inhibition by HS, while still providing enough complement for complement-mediated mAb killing, might be an obstacle. Additionally, assay reproducibility may be difficult without a consistent source of active HS. Figure Disclosures Jill Lindley, Bravos Biosciences (Research Grant or Support)ContraFect Corporation (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support) Timothy B. Doyle, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Brian D. VanScoy, B.S., 3-V Biosciences (Grant/Research Support)Achogen (Grant/Research Support)Amplyx Pharmaceuticals, Inc. (Grant/Research Support)Arixa Pharmaceuticals (Grant/Research Support)Arsanis Inc. (Grant/Research Support)B. Braun Medical Inc. (Grant/Research Support)Basilea Pharmaceutica (Grant/Research Support)BLC USA (Grant/Research Support)Boston Pharmaceuticals (Grant/Research Support)Bravos Biosciences, LLC (Grant/Research Support)Cidara Therapeutics Inc. (Grant/Research Support)Cipla, USA (Grant/Research Support)Corcept Therapeutics (Grant/Research Support)Cumberland Pharmaceuticals (Grant/Research Support)Debiopharm International SA (Grant/Research Support)Discuva Limited (Grant/Research Support)Emerald Lake Technologies (Grant/Research Support)Enhanced Pharmacodynamics (Grant/Research Support)Entasis Therapeutics (Grant/Research Support)E-Scape Bio (Grant/Research Support)Genentech (Grant/Research Support)Geom Therapeutics, Inc. (Grant/Research Support)GlaxoSmithKline (Grant/Research Support)Hoffmann-La Roche (Grant/Research Support)Horizon Orphan LLC (Grant/Research Support)ICPD Biosciences, LLC (Grant/Research Support)Indalo Therapeutics (Grant/Research Support)Insmed Inc. (Grant/Research Support)Institute for Clinical Pharmacodynamics (Employee)Iterum (Grant/Research Support)KBP Biosciences USA (Grant/Research Support)Kyoto Biopharma, Inc. (Grant/Research Support)Matinas (Grant/Research Support)Meiji Seika Pharma Co., Ltd. (Grant/Research Support)Melinta Therapeutics (Grant/Research Support)Menarini Ricerche S.p.A. (Grant/Research Support)Merck & Co., Inc (Grant/Research Support)Mutabilis (Grant/Research Support)Nabriva Therapeutics AG (Grant/Research Support)Naeja-RGM Pharmaceuticals (Grant/Research Support)Nosopharm SAS (Grant/Research Support)Novartis Pharmaceuticals Corp. (Grant/Research Support)NuCana Biomed (Grant/Research Support)Paratek Pharmaceuticals, Inc. (Grant/Research Support)Polyphor, Ltd. (Grant/Research Support)Prothena Corporation (Grant/Research Support)PTC Therapeutics (Grant/Research Support)Rempex Pharmaceuticals (Grant/Research Support)Roche TCRC (Grant/Research Support)Sagimet (Grant/Research Support)scPharmaceuticals Inc. (Grant/Research Support)Scynexis (Grant/Research Support)Spero Therapeutics (Grant/Research Support)TauRx Therapeutics (Grant/Research Support)Tetraphase Pharmaceuticals (Grant/Research Support)Theravance Biopharma Pharmaceutica (Grant/Research Support)USCAST (Grant/Research Support)VenatoRx (Grant/Research Support)Vical Incorporated (Grant/Research Support)Wockhardt Bio AG (Grant/Research Support)Zavante Therapeutics (Grant/Research Support)Zogenix International (Grant/Research Support) Christopher M. Rubino, Pharm.D., 3-V Biosciences (Grant/Research Support)Achogen (Grant/Research Support)Amplyx Pharmaceuticals, Inc. (Grant/Research Support)Arixa Pharmaceuticals (Grant/Research Support)Arsanis Inc. (Grant/Research Support)B. Braun Medical Inc. (Grant/Research Support)Basilea Pharmaceutica (Grant/Research Support)BLC USA (Research Grant or Support)Boston Pharmaceuticals (Grant/Research Support)Bravos Biosciences, LLC (Grant/Research Support, Other Financial or Material Support, member/owner)Cidara Therapeutics Inc. (Grant/Research Support)Cipla, USA (Grant/Research Support)Corcept Therapeutics (Grant/Research Support)Cumberland Pharmaceuticals (Grant/Research Support)Debiopharm International SA (Grant/Research Support)Discuva Limited (Grant/Research Support)Emerald Lake Technologies (Grant/Research Support)Enhanced Pharmacodynamics (Grant/Research Support)Entasis Therapeutics (Grant/Research Support)E-Scape Bio (Grant/Research Support)Genentech (Grant/Research Support)Geom Therapeutics, Inc. (Grant/Research Support)GlaxoSmithKline (Grant/Research Support)Hoffmann-La Roche (Grant/Research Support)Horizon Orphan LLC (Grant/Research Support)ICPD Biosciences, LLC (Grant/Research Support, Other Financial or Material Support, member/owner)Indalo Therapeutics (Grant/Research Support)Insmed Inc. (Grant/Research Support)Institute for Clinical Pharmacodynamics (Employee)Iterum (Grant/Research Support)KBP Biosciences USA (Grant/Research Support)Kyoto Biopharma, Inc. (Grant/Research Support)Matinas (Grant/Research Support)Meiji Seika Pharma Co., Ltd. (Grant/Research Support)Melinta Therapeutics (Grant/Research Support)Menarini Ricerche S.p.A. (Grant/Research Support)Merck & Co., Inc (Grant/Research Support)Mutabilis (Grant/Research Support)Nabriva Therapeutics AG (Grant/Research Support)Naeja-RGM Pharmaceuticals (Grant/Research Support)Nosopharm SAS (Grant/Research Support)Novartis Pharmaceuticals Corp. (Grant/Research Support)NuCana Biomed (Grant/Research Support)Paratek Pharmaceuticals, Inc. (Grant/Research Support)Polyphor, Ltd. (Grant/Research Support)Prothena Corporation (Grant/Research Support)PTC Therapeutics (Grant/Research Support)Rempex Pharmaceuticals (Grant/Research Support)Roche TCRC (Grant/Research Support)Sagimet (Grant/Research Support)scPharmaceuticals Inc. (Grant/Research Support)Scynexis (Grant/Research Support)Spero Therapeutics (Grant/Research Support)TauRx Therapeutics (Grant/Research Support)Tetraphase Pharmaceuticals (Grant/Research Support)Theravance Biopharma Pharmaceutica (Grant/Research Support)USCAST (Grant/Research Support)VenatoRx (Grant/Research Support)Vical Incorporated (Grant/Research Support)Wockhardt Bio AG (Grant/Research Support)Zavante Therapeutics (Grant/Research Support)Zogenix International (Grant/Research Support) Sujata M. Bhavnani, Pharm.D., M.S., FIDSA, 3-V Biosciences (Grant/Research Support)Achogen (Grant/Research Support)Amplyx Pharmaceuticals, Inc. (Grant/Research Support)Arixa Pharmaceuticals (Grant/Research Support)Arsanis Inc. (Grant/Research Support)B. Braun Medical Inc. (Grant/Research Support)Basilea Pharmaceutica (Grant/Research Support)BLC USA (Grant/Research Support)Boston Pharmaceuticals (Grant/Research Support)Bravos Biosciences, LLC (Grant/Research Support, Other Financial or Material Support, member/owner)Cidara Therapeutics Inc. (Grant/Research Support)Cipla, USA (Grant/Research Support)Corcept Therapeutics (Grant/Research Support)Cumberland Pharmaceuticals (Grant/Research Support)Debiopharm International SA (Grant/Research Support)Discuva Limited (Grant/Research Support)Emerald Lake Technologies (Grant/Research Support)Enhanced Pharmacodynamics (Grant/Research Support)Entasis Therapeutics (Grant/Research Support)E-Scape Bio (Grant/Research Support)Genentech (Grant/Research Support)Geom Therapeutics, Inc. (Grant/Research Support)GlaxoSmithKline (Grant/Research Support)Hoffmann-La Roche (Grant/Research Support)Horizon Orphan LLC (Grant/Research Support)ICPD Biosciences, LLC (Grant/Research Support, Other Financial or Material Support, member/owner)Indalo Therapeutics (Grant/Research Support)Insmed Inc. (Grant/Research Support)Institute for Clinical Pharmacodynamics (Employee)Iterum (Grant/Research Support)KBP Biosciences USA (Grant/Research Support)Kyoto Biopharma, Inc. (Grant/Research Support)Matinas (Grant/Research Support)Meiji Seika Pharma Co., Ltd. (Grant/Research Support)Melinta Therapeutics (Grant/Research Support)Menarini Ricerche S.p.A. (Grant/Research Support)Merck & Co., Inc (Grant/Research Support)Mutabilis (Grant/Research Support)Nabriva Therapeutics AG (Grant/Research Support)Naeja-RGM Pharmaceuticals (Grant/Research Support)Nosopharm SAS (Grant/Research Support)Novartis Pharmaceuticals Corp. (Grant/Research Support)NuCana Biomed (Grant/Research Support)Paratek Pharmaceuticals, Inc. (Grant/Research Support)Polyphor, Ltd. (Grant/Research Support)Prothena Corporation (Grant/Research Support)PTC Therapeutics (Grant/Research Support)Rempex Pharmaceuticals (Grant/Research Support)Roche TCRC (Grant/Research Support)Sagimet (Grant/Research Support)scPharmaceuticals Inc. (Grant/Research Support)Scynexis (Grant/Research Support)Spero Therapeutics (Grant/Research Support)TauRx Therapeutics (Grant/Research Support)Tetraphase Pharmaceuticals (Grant/Research Support)Theravance Biopharma Pharmaceutica (Grant/Research Support)USCAST (Grant/Research Support)VenatoRx (Grant/Research Support)Vical Incorporated (Grant/Research Support)Wockhardt Bio AG (Grant/Research Support)Zavante Therapeutics (Grant/Research Support)Zogenix International (Grant/Research Support) Paul G. Ambrose, Pharm.D., FIDSA, 3-V Biosciences (Grant/Research Support)Achogen (Grant/Research Support)Amplyx Pharmaceuticals, Inc. (Grant/Research Support)Arixa Pharmaceuticals (Grant/Research Support)Arsanis Inc. (Grant/Research Support)B. Braun Medical Inc. (Grant/Research Support)Basilea Pharmaceutica (Grant/Research Support)BLC USA (Grant/Research Support)Boston Pharmaceuticals (Grant/Research Support)Bravos Biosciences, LLC (Grant/Research Support, Other Financial or Material Support, member/owner)Cidara Therapeutics Inc. (Grant/Research Support)Cipla, USA (Grant/Research Support)Corcept Therapeutics (Grant/Research Support)Cumberland Pharmaceuticals (Grant/Research Support)Debiopharm International SA (Grant/Research Support)Discuva Limited (Research Grant or Support)Emerald Lake Technologies (Grant/Research Support)Enhanced Pharmacodynamics (Grant/Research Support)Entasis Therapeutics (Grant/Research Support)E-Scape Bio (Grant/Research Support)Genentech (Grant/Research Support)Geom Therapeutics, Inc. (Grant/Research Support)GlaxoSmithKline (Grant/Research Support)Hoffmann-La Roche (Grant/Research Support)Horizon Orphan LLC (Grant/Research Support)ICPD Biosciences, LLC (Grant/Research Support, Other Financial or Material Support, member/owner)Indalo Therapeutics (Grant/Research Support)Insmed Inc. (Grant/Research Support)Institute for Clinical Pharmacodynamics (Employee)Iterum (Grant/Research Support)KBP Biosciences USA (Grant/Research Support)Kyoto Biopharma, Inc. (Grant/Research Support)Matinas (Grant/Research Support)Meiji Seika Pharma Co., Ltd. (Grant/Research Support)Melinta Therapeutics (Grant/Research Support)Menarini Ricerche S.p.A. (Grant/Research Support)Merck & Co., Inc (Grant/Research Support)Mutabilis (Grant/Research Support)Nabriva Therapeutics AG (Grant/Research Support)Naeja-RGM Pharmaceuticals (Grant/Research Support)Nosopharm SAS (Grant/Research Support)Novartis Pharmaceuticals Corp. (Grant/Research Support)NuCana Biomed (Grant/Research Support)Paratek Pharmaceuticals, Inc. (Grant/Research Support)Polyphor, Ltd. (Grant/Research Support)Prothena Corporation (Grant/Research Support)PTC Therapeutics (Grant/Research Support)Rempex Pharmaceuticals (Grant/Research Support)Roche TCRC (Grant/Research Support)Sagimet (Grant/Research Support)scPharmaceuticals Inc. (Grant/Research Support)Scynexis (Grant/Research Support)Spero Therapeutics (Grant/Research Support)TauRx Therapeutics (Grant/Research Support)Tetraphase Pharmaceuticals (Grant/Research Support)Theravance Biopharma Pharmaceutica (Grant/Research Support)USCAST (Grant/Research Support)VenatoRx (Grant/Research Support)Vical Incorporated (Grant/Research Support)Wockhardt Bio AG (Grant/Research Support)Zavante Therapeutics (Grant/Research Support)Zogenix International (Grant/Research Support) Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Bravos Biosciences (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Qpex Biopharma (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Mariana Castanheira, PhD, Affinity Biosensors (Individual(s) Involved: Self): Research Grant or Support; Allergan (Individual(s) Involved: Self): Research Grant or Support; Amicrobe, Inc (Individual(s) Involved: Self): Research Grant or Support; Amplyx Pharma (Individual(s) Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc. (Individual(s) Involved: Self): Research Grant or Support; Astellas (Individual(s) Involved: Self): Research Grant or Support; Basilea (Individual(s) Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center (Individual(s) Involved: Self): Research Grant or Support; BIDMC (Individual(s) Involved: Self): Research Grant or Support; bioMerieux Inc. (Individual(s) Involved: Self): Research Grant or Support; BioVersys Ag (Individual(s) Involved: Self): Research Grant or Support; Bugworks (Individual(s) Involved: Self): Research Grant or Support; Cidara (Individual(s) Involved: Self): Research Grant or Support; Cipla (Individual(s) Involved: Self): Research Grant or Support; Contrafect (Individual(s) Involved: Self): Research Grant or Support; Cormedix (Individual(s) Involved: Self): Research Grant or Support; Crestone, Inc. (Individual(s) Involved: Self): Research Grant or Support; Curza (Individual(s) Involved: Self): Research Grant or Support; CXC7 (Individual(s) Involved: Self): Research Grant or Support; Entasis (Individual(s) Involved: Self): Research Grant or Support; Fedora Pharmaceutical (Individual(s) Involved: Self): Research Grant or Support; Fimbrion Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Fox Chase (Individual(s) Involved: Self): Research Grant or Support; GlaxoSmithKline (Individual(s) Involved: Self): Research Grant or Support; Guardian Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Hardy Diagnostics (Individual(s) Involved: Self): Research Grant or Support; IHMA (Individual(s) Involved: Self): Research Grant or Support; Janssen Research & Development (Individual(s) Involved: Self): Research Grant or Support; Johnson & Johnson (Individual(s) Involved: Self): Research Grant or Support; Kaleido Biosceinces (Individual(s) Involved: Self): Research Grant or Support; KBP Biosciences (Individual(s) Involved: Self): Research Grant or Support; Luminex (Individual(s) Involved: Self): Research Grant or Support; Matrivax (Individual(s) Involved: Self): Research Grant or Support; Mayo Clinic (Individual(s) Involved: Self): Research Grant or Support; Medpace (Individual(s) Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd. (Individual(s) Involved: Self): Research Grant or Support; Melinta (Individual(s) Involved: Self): Research Grant or Support; Menarini (Individual(s) Involved: Self): Research Grant or Support; Merck (Individual(s) Involved: Self): Research Grant or Support; Meridian Bioscience Inc. (Individual(s) Involved: Self): Research Grant or Support; Micromyx (Individual(s) Involved: Self): Research Grant or Support; MicuRx (Individual(s) Involved: Self): Research Grant or Support; N8 Medical (Individual(s) Involved: Self): Research Grant or Support; Nabriva (Individual(s) Involved: Self): Research Grant or Support; National Institutes of Health (Individual(s) Involved: Self): Research Grant or Support; National University of Singapore (Individual(s) Involved: Self): Research Grant or Support; North Bristol NHS Trust (Individual(s) Involved: Self): Research Grant or Support; Novome Biotechnologies (Individual(s) Involved: Self): Research Grant or Support; Paratek (Individual(s) Involved: Self): Research Grant or Support; Pfizer (Individual(s) Involved: Self): Research Grant or Support; Prokaryotics Inc. (Individual(s) Involved: Self): Research Grant or Support; QPEX Biopharma (Individual(s) Involved: Self): Research Grant or Support; Rhode Island Hospital (Individual(s) Involved: Self): Research Grant or Support; RIHML (Individual(s) Involved: Self): Research Grant or Support; Roche (Individual(s) Involved: Self): Research Grant or Support; Roivant (Individual(s) Involved: Self): Research Grant or Support; Salvat (Individual(s) Involved: Self): Research Grant or Support; Scynexis (Individual(s) Involved: Self): Research Grant or Support; SeLux Diagnostics (Individual(s) Involved: Self): Research Grant or Support; Shionogi (Individual(s) Involved: Self): Research Grant or Support; Specific Diagnostics (Individual(s) Involved: Self): Research Grant or Support; Spero (Individual(s) Involved: Self): Research Grant or Support; SuperTrans Medical LT (Individual(s) Involved: Self): Research Grant or Support; T2 Biosystems (Individual(s) Involved: Self): Research Grant or Support; The University of Queensland (Individual(s) Involved: Self): Research Grant or Support; Thermo Fisher Scientific (Individual(s) Involved: Self): Research Grant or Support; Tufts Medical Center (Individual(s) Involved: Self): Research Grant or Support; Universite de Sherbrooke (Individual(s) Involved: Self): Research Grant or Support; University of Iowa (Individual(s) Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics (Individual(s) Involved: Self): Research Grant or Support; University of Wisconsin (Individual(s) Involved: Self): Research Grant or Support; UNT System College of Pharmacy (Individual(s) Involved: Self): Research Grant or Support; URMC (Individual(s) Involved: Self): Research Grant or Support; UT Southwestern (Individual(s) Involved: Self): Research Grant or Support; VenatoRx (Individual(s) Involved: Self): Research Grant or Support; Viosera Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Wayne State University (Individual(s) Involved: Self): Research Grant or Support
Published: 2021

35. A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland

Author: Terri Patricia McVeigh, Karl J. Sweeney, Donal J. Brennan, Una M. McVeigh, Simon Ward, Ann Strydom, Sheila Seal, Katherine Astbury, Paul Donnellan, Joanne Higgins, Maccon Keane, Michael J. Kerin, Carmel Malone, Pauline McGough, Ray McLaughlin, Michael O’Leary, Margaret Rushe, Michael Kevin Barry, Geraldine MacGregor, Michael Sugrue, Ala Yousif, Dhafir Al-Azawi, Eileen Berkeley, Terence J. Boyle, Elizabeth M. Connolly, Carmel Nolan, Elaine Richardson, Claire Giffney, Samantha B. Doyle, Sheila Broderick, William Boyd, Ruaidhri McVey, Thomas Walsh, Michael Farrell, David J. Gallagher, Nazneen Rahman, and Angela J. George
Subjects: Cancer Research, Oncology, Genetics, Genetics (clinical)
Abstract: In the Republic of Ireland (ROI), BRCA1/BRCA2 genetic testing has been traditionally undertaken in eligible individuals, after pre-test counselling by a Clinical Geneticist/Genetic Counsellor. Clinical Genetics services in ROI are poorly resourced, with routine waiting times for appointments at the time of this pilot often extending beyond a year. The consequent prolonged waiting times are unacceptable where therapeutic decision-making depends on the patient's BRCA status. "Mainstreaming" BRCA1/BRCA2 testing through routine oncology/surgical clinics has been implemented successfully in other centres in the UK and internationally. We aimed to pilot this pathway in three Irish tertiary centres. A service evaluation project was undertaken over a 6-month period between January and July 2017. Eligible patients, fulfilling pathology and age-based inclusion criteria defined by TGL clinical, were identified, and offered constitutional BRCA1/BRCA2 testing after pre-test counselling by treating clinicians. Tests were undertaken by TGL Clinical. Results were returned to clinicians by secure email. Onward referrals of patients with uncertain/pathogenic results, or suspicious family histories, to Clinical Genetics were made by the treating team. Surveys assessing patient and clinician satisfaction were sent to participating clinicians and a sample of participating patients. Data was collected with respect to diagnostic yield, turnaround time, onward referral rates, and patient and clinician feedback. A total of 101 patients underwent diagnostic germline BRCA1/BRCA2 tests through this pathway. Pathogenic variants were identified in 12 patients (12%). All patients in whom variants were identified were appropriately referred to Clinical Genetics. At least 12 additional patients with uninformative BRCA1/BRCA2 tests were also referred for formal assessment by Clinical Geneticist or Genetic Counsellor. Issues were noted in terms of time pressures and communication of results to patients. Results from a representative sample of participants completing the satisfaction survey indicated that the pathway was acceptable to patients and clinicians. Mainstreaming of constitutional BRCA1/BRCA2 testing guided by age- and pathology-based criteria is potentially feasible for patients with breast cancer as well as patients with ovarian cancer in Ireland.
Published: 2022

36. Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against Pseudomonas aeruginosa and Klebsiella pneumoniae Isolates from United States Medical Centers in 2016–2018

Author: Helio S. Sader, Cecilia G Carvalhaes, Mariana Castanheira, Timothy B Doyle, and Jennifer M. Streit
Subjects: Microbiology (medical), Klebsiella pneumoniae, medicine.drug_class, Immunology, Cephalosporin, medicine.disease_cause, Microbiology, Meropenem, 03 medical and health sciences, polycyclic compounds, Medicine, 030304 developmental biology, Pharmacology, 0303 health sciences, biology, 030306 microbiology, business.industry, Pseudomonas aeruginosa, Broth microdilution, biochemical phenomena, metabolism, and nutrition, bacterial infections and mycoses, Ceftazidime/avibactam, biology.organism_classification, Antimicrobial, Amikacin, business, medicine.drug
Abstract: Very few antimicrobial agents remain active against Pseudomonas aeruginosa and Klebsiella pneumoniae in some geographic regions. We evaluated the in vitro activity of ceftazidime-avibactam, ceftolozane-tazobactam, and comparator agents against 6,210 P. aeruginosa and 6,041 K. pneumoniae isolates consecutively collected from 85 U.S. medical centers across 37 states in 2016-2018. Antimicrobial susceptibility was determined by reference broth microdilution method. K. pneumoniae isolates found to have elevated MICs for broad-spectrum cephalosporins were submitted to whole-genome sequencing analysis to detect resistance genes. Ceftazidime-avibactam (97.1% susceptible [S]) and ceftolozane-tazobactam (97.0%S) were the most active compounds against P. aeruginosa and retained activity against meropenem-nonsusceptible (88.5-89.0%S), piperacillin-tazobactam-nonsusceptible (86.6-87.0%S), and other resistant subsets of isolates. The most active agents against K. pneumoniae per CLSI criteria were ceftazidime-avibactam (>99.9%S), amikacin (98.4%S), and meropenem (97.1%S). Ceftolozane-tazobactam was active against 95.3% of K. pneumoniae but showed limited activity against extended-spectrum β-lactamase and carbapenemase producers (82.9% and 0.0%S, respectively).
Published: 2021

37. The theory of emerging adulthood: parents’ experience of their child’s transition to college

Author: Grainne M. O’Donnell and Colleen B. Doyle
Subjects: Higher education, business.industry, Transition (fiction), education, Key (cryptography), Psychology, business, Education, Developmental psychology
Abstract: The transition to college is a critical determinant of student success in higher education. Increasingly, students’ parents play a key role in supporting their sons and daughters as they adjust to ...
Published: 2020

38. Risk of Juvenile Idiopathic Arthritis and Rheumatoid Arthritis in Patients With Celiac Disease: A Population-Based Cohort Study

Author: John B. Doyle, Benjamin Lebwohl, Johan Askling, Anders Forss, Peter H.R. Green, Bjorn Roelstraete, Jonas Söderling, and Jonas F. Ludvigsson
Subjects: Adult, Cohort Studies, Arthritis, Rheumatoid, Celiac Disease, Hepatology, Incidence, Gastroenterology, Humans, Child, Arthritis, Juvenile
Abstract: Celiac disease (CD) is associated with many immune-mediated conditions, but a definitive epidemiological association between CD and juvenile idiopathic arthritis (JIA) or rheumatoid arthritis (RA) has not been established. We quantified the risk of JIA and RA among patients with CD using a population-based cohort.We identified patients diagnosed with biopsy-proven CD between 2004 and 2017 using data from a national histopathology cohort in Sweden. Each patient was matched by age, sex, calendar year, and geographic region to reference individuals in the general population. We calculated the incidence and estimated the relative risk, through Cox proportional hazards models, of JIA in individuals with CD aged18 and of RA in individuals with CD aged ≥18.We identified 24,014 individuals with CD who were matched to 117,397 reference individuals from the general population. Among individuals aged18, the incidence rate of JIA was 5.9 per 10,000 person-years in patients with CD and 2.2 per 10,000 person-years in the general population (n events = 40 and 73, respectively; hazard ratio [HR] 2.68, 95% confidence interval 1.82-3.95) over a follow-up of 7.0 years. Among individuals aged ≥ 18, the incidence of RA was 8.4 per 10,000 person-years in CD and 5.1 per 10,000 person-years in matched comparators (n events = 110 and 322, respectively; HR 1.70, 95% confidence interval 1.36-2.12) over a follow-up of 8.8 years.Among children with CD, JIA develops nearly 3 times as often as it does in the general population, and among adults with CD, RA occurs nearly 2 times as often. Clinicians caring for patients with CD with joint symptoms should have a low threshold to evaluate for JIA or RA.
Published: 2022

39. MR-Guided Radiation Therapy With Concurrent Gemcitabine/Nab-Paclitaxel Chemotherapy in Inoperable Pancreatic Cancer: A TITE-CRM Phase I Trial

Author: Hyun Kim, Jeffrey R. Olsen, Olga L. Green, Re-I Chin, William G. Hawkins, Ryan C. Fields, Chet Hammill, Majella B. Doyle, William Chapman, Rama Suresh, Benjamin Tan, Katrina Pedersen, Brandi Jansen, Todd A. DeWees, Esther Lu, Lauren E. Henke, Shahed Badiyan, Parag J. Parikh, Michael C. Roach, Andrea Wang-Gillam, and Kian-Huat Lim
Subjects: Cancer Research, Radiation, Oncology, Radiology, Nuclear Medicine and imaging
Abstract: Ablative radiation therapy for borderline resectable or locally advanced pancreatic ductal adenocarcinoma (BR/LA-PDAC) may limit concurrent chemotherapy dosing and usually is only safely deliverable to tumors distant from gastrointestinal organs. Magnetic resonance guided radiation therapy may safely permit radiation and chemotherapy dose escalation.We conducted a single-arm phase I study to determine the maximum tolerated dose of ablative hypofractionated radiation with full-dose gemcitabine/nab-paclitaxel in patients with BR/LA-PDAC. Patients were treated with gemcitabine/nab-paclitaxel (1000/125 mg/mThirty patients enrolled (March 2015-February 2019), with 26 evaluable patients (2 progressed before radiation, 1 was determined ineligible for radiation during planning, 1 withdrew consent). One DLT was observed. The DLT rate was 14.1% (3.3%-24.9%) with a maximum tolerated dose of gemcitabine/nab-paclitaxel (1000/100 mg/mFull-dose gemcitabine/nab-paclitaxel with ablative magnetic resonance guided radiation therapy dosing is safe in patients with BR/LA-PDAC, with promising LPFS and DMFS.
Published: 2022

40. AHPBA Webinar about Covid-19: lessons learned responding to a pandemic

Author: Sean P. Cleary, Nicolas Demartines, Maria B. Doyle, Timothy M. Pawlik, Michael I. D’Angelica, and Tara S. Kent
Subjects: 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), COVID19, Pneumonia, Viral, MEDLINE, Digestive System Neoplasms, Global Health, Article, surgery, Betacoronavirus, Pandemic, medicine, Global health, Humans, Pandemics, Digestive System Surgical Procedures, Internet, hepato-pancreato-biliary, response, Hepatology, biology, SARS-CoV-2, Viral Epidemiology, business.industry, pandemic, Gastroenterology, COVID-19, Congresses as Topic, medicine.disease, biology.organism_classification, Virology, Pneumonia, Coronavirus Infections, business, Delivery of Health Care
Published: 2020

41. Surgical Therapy for Pediatric Hepatoblastoma in the USA over the Last Decade: Analysis of the National Cancer Database

Author: David G. Brauer, Yumirle P. Turmelle, Maria B. Doyle, Janis Stoll, Michelle Nadler, Sakil Kulkarni, Adeel S. Khan, and William C. Chapman
Subjects: Univariate analysis, medicine.medical_specialty, Hepatoblastoma, Chemotherapy, business.industry, medicine.medical_treatment, Gastroenterology, Pediatric hepatoblastoma, Cancer, Disease, Liver transplantation, medicine.disease, Radiation therapy, 03 medical and health sciences, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Internal medicine, medicine, 030211 gastroenterology & hepatology, business
Abstract: Hepatoblastoma (HB) is a rare childhood malignancy with hepatic resection (HR) or liver transplantation (LT) providing the best chance of cure. In this study, we analyze the National Cancer Database lacks (NCDB) to compare outcomes following HR and LT for HB. Review of the US experience with surgical (HR and LT) management of pediatric (
Published: 2020

42. Role of yttrium-90 selective internal radiation therapy in the treatment of liver-dominant metastatic colorectal cancer: an evidence-based expert consensus algorithm

Author: D. Rohan Jeyarajah, Joseph Kim, David A. Iannitti, Paul D. Hansen, Thavam Thambi-Pillai, Brendan C. Visser, N. Joseph Espat, and Maria B. Doyle
Subjects: 0301 basic medicine, Chemotherapy, Evidence-based practice, Colorectal cancer, business.industry, medicine.medical_treatment, Selective internal radiation therapy, Gastroenterology, Expert consensus, Context (language use), Review Article, Disease, medicine.disease, Palliative Therapy, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, medicine, business, Algorithm
Abstract: Surgical resection of colorectal liver metastases is associated with greater survival compared with non-surgical treatment, and a meaningful possibility of cure. However, the majority of patients are not eligible for resection and may require other non-surgical interventions, such as liver-directed therapies, to be converted to surgical eligibility. Given the number of available therapies, a general framework is needed that outlines the specific roles of chemotherapy, surgery, and locoregional treatments [including selective internal radiation therapy (SIRT) with Y-90 microspheres]. Using a data-driven, modified Delphi process, an expert panel of surgical oncologists, transplant surgeons, and hepatopancreatobiliary (HPB) surgeons convened to create a comprehensive, evidence-based treatment algorithm that includes appropriate treatment options for patients stratified by their eligibility for surgical treatment. The group coined a novel, more inclusive phrase for targeted locoregional tumor treatment (a blanket term for resection, ablation, and other emerging locoregional treatments): local parenchymal tumor destruction therapy. The expert panel proposed new nomenclature for 3 distinct disease categories of liver-dominant metastatic colorectal cancer that is consistent with other tumor types: (I) surgically treatable (resectable); (II) surgically untreatable (borderline resectable); (III) advanced surgically untreatable (unresectable) disease. Patients may present at any point in the algorithm and move between categories depending on their response to therapy. The broad intent of therapy is to transition patients toward individualized treatments where possible, given the survival advantage that resection offers in the context of a comprehensive treatment plan. This article reviews what is known about the role of SIRT with Y-90 as neoadjuvant, definitive, or palliative therapy in these different clinical situations and provides insight into when treatment with SIRT with Y-90 may be appropriate and useful, organized into distinct treatment algorithm steps.
Published: 2020

43. Ten Years of Green Manuring and Biofumigation Alters Soil Characteristics and Microbiota

Author: Brianna A.R. Walker, Shane M. Powell, Robert S. Tegg, Richard B. Doyle, Ian G. Hunt, and Calum R. Wilson
Subjects: History, Ecology, Polymers and Plastics, Soil Science, Business and International Management, Agricultural and Biological Sciences (miscellaneous), Industrial and Manufacturing Engineering
Published: 2022

44. In Vitro Selection of Enterobacter cloacae with Cefepime, Meropenem, and Ceftazidime-Avibactam Generates Diverse Resistance Mechanisms

Author: Mariana Castanheira, Jill Lindley, Timothy B. Doyle, Andrew P. Davis, and Helio S. Sader
Subjects: Microbiology (medical), Infectious Diseases, Pharmacology (medical), General Medicine
Abstract: We submitted 5 E. cloacae isolates to 10-day serial passage in broth microdilution with cefepime, meropenem, or ceftazidime-avibactam to evaluate MIC increases and resistance mechanisms after exposure. Post-exposure isolates displaying2-fold changes from the parent isolate were analyzed alongside their parent isolate. Overall increase is MIC results of 4- to 256-fold (median: 16-fold) were noted after cefepime exposure, 16- to 128-fold (64-fold) after meropenem, and 2- to 32-fold (8-fold) after ceftazidime-avibactam. Post-exposure isolates had diverse mechanisms identified using a combination of short- and long-whole genome sequencing. All agents selected for AmpC alterations in one isolate set. OmpC and TetA/AcrR regulator alterations were noted in meropenem and ceftazidime-avibactam post-exposure isolates of the same set. Other mutations in AmpC were noted when isolates were exposed to cefepime or ceftazidime-avibactam. A premature stop codon in the cell division inhibitor protein MioC was observed when one parent isolate was exposed to any of the agents, suggesting a cell persistence mechanism. Mutations in less common transporter systems and protein synthesis components were also noted. Cross-resistance to other β-lactams occurred with all agents and resistance mechanisms were diverse with some not usually associated with β-lactam resistance in Enterobacterales. This initial evaluation suggests that cefepime and meropenem select for isolates with higher MIC values when compared to ceftazidime-avibactam. Further studies evaluating these findings should be performed for other species for which the primary β-lactam resistance mechanism is not gene acquisition. These studies should evaluate these observations in vivo to evaluate their translation into patient treatment policies.
Published: 2023

45. Composite Length of Stay, An Outcome Measure of Postoperative and Readmission Length of Stays in Pancreatoduodenectomy

Author: William C. Chapman, Adeel S. Khan, Ryan C. Fields, Majella B. Doyle, Gregory A. Williams, Chet W. Hammill, William G. Hawkins, Steven M. Strasberg, Dominic E. Sanford, and Jingxia Liu
Subjects: medicine.medical_specialty, Logistic regression, Patient Readmission, Article, Pancreaticoduodenectomy, 03 medical and health sciences, Postoperative Complications, 0302 clinical medicine, Clos network, Risk Factors, Outcome Assessment, Health Care, Area under curve, Humans, Medicine, Retrospective Studies, business.industry, Gastroenterology, Outcome measures, Length of Stay, Readmission rate, Surgery, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Complication, business
Abstract: PURPOSE: Postoperative length of stay (PLOS) and readmission rate are pancreatoduodenectomy (PD) outcome measures, which are reported individually but may be interrelated. The purpose of this study was to evaluate how well a composite length of stay measure (CLOS) that included PLOS and readmission length of stay describes outcomes. To do so, we evaluated how well CLOS correlated to postoperative complications absolutely and compared to PLOS. METHODS: A total of 668 PDs performed between 2011 and 2018 were evaluated. CLOS was calculated from PLOS and readmission length of stay. Complication severity was judged by the Modified Accordion Grading System (MAGS). Multinomial logistical regression models (MLRM) were used to investigate the relationship between either PLOS or CLOS and complications. Multilevel and pairwise area under curves (AUC) using SAS macro %MultAUC were provided for both models. RESULTS: A total of 432 of 668 patients (65%) developed complications. One hundred seventy-seven patients (27%) were readmitted. Mean PLOS was 10.2 days (7.1 SD) and mean CLOS was 12.3 days (10.1 SD). PLOS and CLOS both were correlated linearly to MAGS grade. Spearman correlation coefficient for CLOS vs. MAGS of 0.68 was higher than that of 0.49 for PLOS vs. MAGS. Multilevel AUC from MLRM using PLOS was 0.66, but multilevel AUC from MLRM using CLOS was 0.71. DISCUSSION: CLOS provides an accurate estimate of hospital day utilization per patient for PD, reflecting not only the basal hospital recovery time for PD but the added time needed because of readmissions due to complications. It is tightly correlated to number and severity of postoperative complications.
Published: 2019

46. FeRAM using Anti-ferroelectric Capacitors for High-speed and High-density Embedded Memory

Author: S. -C. Chang, N. Haratipour, S. Shivaraman, C. Neumann, S. Atanasov, J. Peck, N. Kabir, I. -C. Tung, H. Liu, B. Krist, A. Oni, S. Sung, B. Doyle, G. Allen, C. Engel, A. Roy, T. Hoff, H. Li, F. Hamzaoglu, R. Bristol, M. Radosavljevic, B. Turkot, M. Metz, I. Young, J. Kavalieros, and U. Avci
Published: 2021

47. Body mass index and additional risk factors for cancer in adults with cystic fibrosis

Author: Rita M, Knotts, Zhezhen, Jin, John B, Doyle, Claire, Keating, Emily, DiMango, and Julian A, Abrams
Subjects: Adult, Cystic Fibrosis, Risk Factors, Neoplasms, Humans, Cystic Fibrosis Transmembrane Conductance Regulator, Exocrine Pancreatic Insufficiency, Body Mass Index, Retrospective Studies
Abstract: Adults with cystic fibrosis (CF) have an increased risk of a variety of cancers, notably gastrointestinal cancers. In CF higher body mass index (BMI) is associated with improved long-term outcomes, yet in the general population high BMI is associated with increased cancer risk. We aimed to delineate associations between BMI and other factors with cancer risk in adults with CF.This was a retrospective cohort study using CF Foundation Patient Registry data from 1992 to 2015. Data were collected on age, sex, CFTR mutation class, pancreatic insufficiency, and annualized data on BMI and FEV1. The primary analysis was the association between BMI and cancer, with secondary analyses focused on BMI trajectory. Multivariable logistic regression was performed, with analyses stratified by history of transplant.Of 26,199 adults with CF, 446 (1.7%) had cancer diagnosed by histology at a mean age of 40.0 years (SD 12.2), with a higher proportion of transplanted patients developing cancer (137 (3.8%) v 309(1.4%), p 0.001). Among non-transplanted patients, there was no association between BMI and cancer (p for trend = 0.43). Pancreatic insufficiency (p 0.01) and higher FEV1 (p 0.01) were associated with increased cancer risk. In transplanted patients, higher BMI was associated with reduced risk of cancer (p for trend = 0.04). Older age was associated with increased risk in both groups (p 0.001). BMI trajectories were not associated with cancer risk in either group.Higher BMI is associated with a reduced risk of cancer in transplanted adults with CF. Pancreatic insufficiency is a risk factor for cancer in non-transplanted CF patients.
Published: 2021

48. Soil microbial community dynamics during ryegrass green manuring and brassica biofumigation

Author: Brianna A.R. Walker, Shane M. Powell, Robert S. Tegg, Richard B. Doyle, Ian G. Hunt, and Calum R. Wilson
Subjects: Ecology, Soil Science, Agricultural and Biological Sciences (miscellaneous)
Published: 2022

49. A Tangent Based Method for Robot Path Planning.

Author: A. B. Doyle and Dewi I. Jones
Published: 1994
Full Text: View/download PDF

50. Impact of charged dust on the propagation of driven low frequency, electrostatic fluctuations in a magnetized plasma

Author: B. Doyle, W. L. Burdett, S. Williams, Edward Thomas, Robert L. Merlino, Marlene Rosenberg, and Uwe Konopka
Subjects: Physics, Dusty plasma, Solar System, Field (physics), Saturn, Astrophysics, Plasma, Particulates, Low frequency, complex mixtures, respiratory tract diseases
Abstract: The role of charged, solid particulate matter (i.e., "dust"’ in plasmas has been considered for several decades. However, beginning with observations of structures in the dust tails of comets and the Voyager observations of radial structures ("spokes"’ in Saturn’s rings, the role of charged dust in the solar system led to the emergence of the field of "dusty" (alternatively, "complex"’ plasmas. Since the early 1990’s there has been a complementary effort in the area of laboratory dusty plasmas that has, over almost four decades, led to the observation of numerous types of plasma and dusty plasma behavior – ranging from appearance of strongly-coupled, self-organized dusty plasma crystals to new types of collective, dust-driven modes, such as the dust acoustic and dust density waves.
Published: 2021

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Category

Publication Type

Journal

Region

Database

Publisher

750 results on '"B. Doyle"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources